What is the main business of Abastroke?

The main business activity of Abastroke focuses on research and experimental development on biotechnology.

When was the company founded?

The company was registered in the Polish National Court Register (KRS) on April 29, 2020.

Where is the headquarters located?

The headquarters is located at: ul. Warszawska 3, 31-155 Kraków.

Who is on the management board?

The management board consists of: Michał Sebastian Ryś (President of the Management Board).

What is the share capital?

The share capital of the company is PLN 45,450 (approx. $12,277).

What period do the latest financial data cover?

The latest available financial statement covers the period from January 1, 2024 to December 31, 2024.

What was the revenue?

In 2024, the company generated total revenue of $36,502, representing a decrease of 93.0% compared to 2023.

Yes, the company recorded a net profit of $11,782 in 2024.

Which cost dominates operating expenses?

The largest operating cost category falls under cost of goods and materials sold. This category amounted to $24,512 in 2024, representing 651% of all operating expenses.

Abastrokesp. z o.o.

Research and experimental development on biotechnology

KRS: NIP: REGON:

Overview

Status

Active

Registry date

2020-04-29

Share capital

45,450.00 PLN

Activity description

Abastroke develops digital tools for home rehabilitation of post-stroke cognitive deficits, combining ABA methodology with machine-learning algorithms. In a 2023–2024 clinical study of 74 participants, the group using the app improved its MoCA score by an average of 3.69 points, compared with 2.00 points in the control group.

Registered address

ul. Warszawska 3/3, 31-155 Kraków, Poland

Website

abastroke.com

Electronic delivery address

AE:PL-86260-54223-CSJJD-14

Financials

Revenue history (in k)

From the notes

Current income tax (CIT due)	$0
Profit allocation	No decision
Loans and borrowings	$436,401

Filing timeliness

1 of 6 financial statements was filed late (for 2021, 69 days late).

2025filed
202414/07/2025
202309/05/2024
202229/06/2023
202122/09/2022
202027/07/2021

Filed on timeDelayFiling deadline

Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.

Statistics

How the company ranks by revenue within its industry, region and across Poland in 2025.

Results vs industry

Revenue

This companyUSD 507.48kMedianUSD 55.24kAverageUSD 2.71m

Net profit

This companyUSD -629.88kMedianUSD -1.27kAverageUSD -91.85k

Operating costs

This companyUSD 1.10mMedianUSD 65.85kAverageUSD 2.66m

Assets

This companyUSD 2.03mMedianUSD 133.19kAverageUSD 3.03m

Industry

Offer

Rehabilitation application
Neurological rehabilitation
Cognitive exercises

Certifications: ISO 13485, ISO 27001

Trademarks

Abastroke currently holds no active trademarks with the Polish Patent Office. 2 marks have expired or were not registered. The first mark was filed in 2021.

Mark	Number	Classes	Status	Protected until
ABAStroke(word)	Z.527309	42, 44	Proceedings discontinued	–
ABAStroke(word)	Z.524116	42	Not registered	–

Mark	Protected until
ABAStroke(word)	–
ABAStroke(word)	–

Authorized Representatives

Michał Sebastian Ryś – President of the Management Board

Manner of representation

The company is represented by two members of the management board acting jointly, or by a member of the management board together with a commercial proxy. If a member of the management board is appointed by any of the investors in the manner described in §17 section 2 of the company's articles of association, the participation of the member of the management board appointed by the investor is required to represent the company (i.e. joint representation with the member of the management board appointed by the investor).

Ownership

Owner	Shares	Share value	Stake
Life Science Innovations sp. z o.o. + limited partnership	112	$1,512.70	12.3212%
N50 Cyprus Limited	114	$1,539.71	12.5413%
Piotr Jeleński Foundation Fundacja Rodzinna	112	$1,512.70	12.3212%
Michał Sebastian Ryśage 40	276	$3,727.71	30.363%
Others	295	$3,984.33	32.4533%

Beneficial owners

Person	Rights

Bank accounts

Registered as a VAT taxpayer on 2020-05-01.

ING Bank Śląski
18 1050 1025 1000 0090 8572 1851
ING Bank Śląski
64 1050 1025 1000 0090 8141 0343
ING Bank Śląski
42 1050 1025 1000 0090 8088 8879

Debt

No entries in the National Debtors Register (KRZ).

Public aid

6 public aid cases recorded, with a total value of $2,537,670.

Grant date	Purpose	Gross amount	Granting body
Apr 22, 2025	Aid for research and development projects: industrial research	$1.1M$1,053,611	Prezes Agencji Badań Medycznych
Sep 3, 2024	De minimis aid (in accordance with Commission Regulation 2023/2831)	$60,985$60,985	Marszałek Województwa Małopolskiego
Jan 25, 2022	De minimis aid (in accordance with Commission Regulation No 1407/2013 or earlier)	$19,045$19,045	Polska Agencja Inwestycji I Handlu S.A.

European Funds

Start	Project	EU co-financing	Programme
2022-01-01	ABAStroke - personalized mobile rehabilitation of post-stroke cognitive deficits	$1M$1,021,901	Operational Programme Smart Growth

Competitors

	Name	Revenue	Website
	Uhura Bionicssp. z o.o.	$88,274.48	uhura.pl

Change history

Date	Event
2026-06-15	Share capital increase (38,800.00 PLN → 45,450.00 PLN)
2024-02-15	Address change (Ul. Krakowska 5/23, 31-062, Kraków → Ul. Warszawska 3/3, 31-155, Kraków)
2024-02-15	Share capital increase (37,400.00 PLN → 38,800.00 PLN)
2023-03-29	Share capital increase (28,300.00 PLN → 37,400.00 PLN)
2022-04-14	Share capital increase (14,000.00 PLN → 28,300.00 PLN)

FAQ

Last updated: 2026-06-15